Skin and Connective Tissue Diseases

445 trials 165 recruiting

Filter these 445 trials by phase, country and sponsor.

Open in Search →

A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending

2025-524078-40-00 Chronic Spontaneous Urticaria 5
Efficacy and safety of allogenic cultured Adipose-derived mesenchymal stromal cell injections on MoUth fibrosis and handicap in patients wit… Pending

2024-518516-39-00 Systemic sclEroderma 4
FESTIVAL_Fecal transplantation in Hidradenitis suppurativa : a pilot study Pending

2024-519003-99-00 Hidrdenitis suppurative 4
“A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental v… Pending

2025-523266-24-00 Vitiligo 4
Treatment of low-flow vascular malformations with bleomycin electrosclerotherapy (BEST) Pending

2025-524123-45-00 VASCULAR MALFORMATION 4
AN OUTPATIENT, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, CROSS-OVER STUDY OF THE EFFICACY OF ARS-2 IN PATIENTS WITH CHRONIC SPONTANEOU… Pending

2025-521930-27-00 Chronic Spontaneous Urticaria (CSU) 4
New therapeutic approach to Toxic Epidermal Necrolysis (TEN) using anti-CD38+ antibodies in the active phase of the disease – Phase I/II stu… Pending

2024-512164-63-00 Toxic Epidermal Necrolysis 9
Comparison of creams for the treatment of dry foot of persons with diabetes. Pending

2022-500907-27-01 xerotic skin on foot of subjects with diabetes 6
A Phase 4 Mechanistic Longitudinal Study to Evaluate the Impact of EARLY Risankizumab Treatment on TRM Cell Levels in Moderate-to-Severe Pso… Pending

2025-521424-30-00 Psoriasis 6
Randomised study to evaluate metformin as an enhancer treatment and also to find out if it is effective and safe in daylight therapy for ski… Pending

2025-520798-38-00 Actinic keratoses 4
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis Pending

2025-524205-32-00 Atopic Dermatits 1
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri… Recruiting

2025-523404-74-00 Prurigo Nodularis 4 2026-05-26
Phase 2 Proof-of-Concept Study of LAD328 in Adults with Hidradenitis Suppurativa Recruiting

2025-521865-29-00 moderate-to-severe hidradenitis suppurativa 4 2026-04-30
L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) Recruiting

2025-523229-16-00 locally advanced basal cell carcinoma patients 4 2026-04-27
L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma Recruiting

2025-523231-19-00 Cutaneous Squamous Cell Carcinoma 4 2026-04-27
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
Dose-finding study of LAD603 in adults with alopecia areata Recruiting

2025-523342-27-00 Alopecia areata 4 2026-04-10
Pediatric Safety Follow-up Study of Prior Treatment with Romosozumab for Osteogenesis Imperfecta Recruiting

2023-503293-21-00 Osteogenesis Imperfecta 5 2026-03-25
A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product Recruiting

2024-520222-11-00 Hematological or solid tumor malignancies or autoimmune 3 2026-03-03
Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II stu… Recruiting

2024-513155-32-00 chronic spontaneous urticaria 4 2026-03-02
Zasocitinib in Nonsegmental Vitiligo Recruiting

2025-522309-40-00 Non-segmental vitiligo 4 2026-02-11
Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting

2022-503140-41-00 Melanoma 5 2025-12-19
A Long-Term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older with Moderate to Severe Eczema Recruiting

2023-509124-18-00 Moderate-to-Severe Atopic Dermatitis 5 2025-12-19
Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting

2025-521293-34-00 Moderate-to-severe hidradenitis suppurativa 4 2025-12-09